

AUTHOR QUERIES

DATE 5/24/2014

JOB NAME CORNEA

ARTICLE CORNEA-D-14-00223

QUERIES FOR AUTHORS Kymionis et al

THIS QUERY FORM MUST BE RETURNED WITH ALL PROOFS FOR CORRECTIONS

- AU1) Please check the introduced running head.
- AU2) Please provide the department (if any) in affiliations.
- AU3) Please confirm conflicts of interest statement.
- AU4) Please check and approve the change in “The PED ...”.
- AU5) Please check the keywords inserted as given in the PDF file.
- AU6) Please note and approve the changes in “A 36-year-old ...”.
- AU7) Please indicate if “RGTAs compose a” should read “RGTAs belong to a ”.
- AU8) Please check the change to “In a recent ...” and amend if necessary.

Combined Topical Application of a Regenerative Agent With a Bandage Contact Lens for the Treatment of Persistent Epithelial Defects

George D. Kymionis, MD, PhD,*† Dimitrios A. Liakopoulos, MD,* Michael A. Grentzelos, MD,*
Vasilios F. Diakonis, MD, PhD,* Nektarios E. Klados, MD,* Konstantinos I. Tsoulharas, MD,*
Miltiadis K. Tsilimbaris, MD, PhD,* and Ioannis G. Pallikaris, MD, PhD*

Purpose: The aim of this study was to report 3 cases of persistent epithelial defects (PEDs) successfully treated with the combined topical application of a regenerative agent (RGTA; Cacicol20, OTR3, Paris, France) with a bandage contact lens (BCL).

Methods: This is a case series.

Results: Three patients suffering from a PED for 4–8 weeks and unresponsive to conventional therapy were treated with the combined application of an RGTA (Cacicol20) and a silicon hydrogel BCL. The PED healed in all patients after 4–21 days, and no side effects were noted.

AU4

Conclusions: The combination of an RGTA (Cacicol20) with a BCL seems to be an effective treatment for PED.

Key Words: regenerative agent (RGTA), Cacicol, bandage contact lens (BCL), persistent epithelial defect (PED)

AU5

(*Cornea* 2014;00:1–5)

Persistent epithelial defects (PEDs) may result from both ocular and systemic diseases such as dry eye, corneal epithelial stem cell deficiency, neurotrophic keratopathy, and diabetes mellitus. PEDs could lead to stromal degradation and thinning, whereas in advance cases, the cornea may get perforated. Treatment approaches for PEDs include the use of artificial tears, punctal plugs, eye patching, tarsorrhaphy, bandage contact lens (BCL), fibronectin, autologous serum eye drops, nerve growth factor, amniotic membrane graft, and limbal stem cell transplantation.^{1–6} BCL has shown to be an effective option for the reepithelialization process.^{6,7} Combined treatment for PED has also been reported; this includes the combination of BCL with serum eye drops or epidermal growth factor.^{8–10}

Received for publication March 25, 2014; revision received April 16, 2014; accepted April 27, 2014. Published online ahead of print XX XX, XXXX. From the *Faculty of Medicine, Vardinoyiannion Eye Institute of Crete (VEIC), University of Crete, Heraklion, Crete, Greece; and †Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL.

AU2

Supported in part by the special research account of the University of Crete. The authors have no funding or conflicts of interest to disclose.

AU3

Reprints: George D. Kymionis, MD, PhD, Faculty of Medicine, Vardinoyiannion Eye Institute of Crete (VEIC), University of Crete, Heraklion, Crete 71003, Greece (e-mail: kymionis@med.uoc.com).

Copyright © 2014 by Lippincott Williams & Wilkins

Regenerating agents (RGTA) are a new pharmaceutical family of biodegradable glucose-based polymers engineered to replace heparan sulfates.¹¹ In a recent study, Aifa et al¹² reported complete corneal healing in 8 of 11 patients with neurotrophic ulcers after topical treatment with an RGTA (Cacicol20, OTR3, Paris, France). Cacicol20 is an RGTA that binds to matrix proteins and protects them from proteolysis; this allows the extracellular matrix microenvironment to get restored to its original architecture.^{11–13}

In this article, we present 3 patients with PEDs who were successfully treated with an RGTA (Cacicol20) combined with BCL.

CASE SERIES

Three patients (3 eyes) with a PED for 4–8 weeks and unresponsive to conventional therapy were enrolled in our case series. All the patients received a combined treatment of RGTA (Cacicol20) with a silicon hydrogel BCL (PremiO, Asmofilcon A; Menicon, Nagoya, Japan). At the time of referral of the patients, the previous topical treatment was discontinued and only artificial tears (4 times per day), along with a silicon hydrogel BCL (PremiO, Asmofilcon A; Menicon), were applied for 7 days to have a washout period of any topical drug; only in case 3 (a patient 4 months after penetrating keratoplasty) were topical steroids maintained at the same dosage (dexamethasone 0.1% eye drops twice daily, Maxidex; Alcon Lab Inc) during the combined treatment.

Institutional Review Board approval was obtained, and all patients were appropriately informed before their participation in the study about the possible outcomes and the current clinical experience. The patients provided a written informed consent in accordance with institutional guidelines, according to the Declaration of Helsinki.

After the washout period, the BCL was replaced with a new one (same type), and topical application of an RGTA (Cacicol20) was prescribed (instillation of 1 drop daily). The use of artificial tears was continued with the same dosage (4 times per day).

Case 1

A 53-year-old woman was referred to our department for the management of a PED in her left eye, which was

caused by neurotrophic keratopathy. The PED was resistant to conventional treatment for 8 weeks. Conventional therapy during the 8-week period included the use of BCL, pressure patch, short-acting absorbable punctal plugs, serum eye drops, and several topical eye drops (eg, tobramycin, fluorometholone, dexamethazone, and moxifloxacin). At the time of referral, slit-lamp examination showed a central corneal epithelial defect [1.6 mm (height) \times 2.4 mm (width)] with underlying and surrounding stromal opacification (Figs. 1A, B). Mild conjunctival hyperemia was noticed.

No improvement in the epithelial defect occurred during the washout period (7 days with BCL and artificial tears used 4 times daily). One week after the combined treatment commenced, the dimensions of the epithelial defect decreased to 1.0 mm (height) \times 1.3 mm (width) (Figs. 1C, D). Two weeks later (3 weeks after the treatment commenced), slit-lamp examination showed a complete corneal epithelial healing (Figs. 1E, F), and the combined treatment was discontinued. There was no event of recurrence during the 4-month follow-up.

Case 2

A 62-year-old woman referred to our department for the management of a PED in her left eye. The PED arose immediately after her cataract surgery and was resistant to

the conventional treatment for 4 weeks. The patient's regimen over the 4-week period included BCL, pressure patch, topical antibiotic/steroid eye drops (chloramphenicol/dexamethasone; Dispersadron C, Laboratories Thea, Clermont-Ferrand, France), systemic medication (Acyclovir), short-acting absorbable punctal plugs, and artificial tears. At presentation, slit-lamp examination showed an extended epithelial defect [8.2 mm (height) \times 6.4 mm (width)] and corneal edema with Descemet folds (Figs. 2A, B). Intense conjunctival hyperemia and mild blepharitis were noticed while the pupil was in semidilation.

The epithelial defect did not improve during the washout period. Four days after the introduction of the combined treatment, complete corneal epithelial healing was achieved (Figs. 2C, D). Corneal stromal edema and Descemet folds were diminished, and dexamethasone 0.1% eye drops (Maxidex; Alcon Lab Inc) were prescribed. Two weeks later, the corneal stromal pathology was restored; the slit-lamp examination revealed map dot dystrophy, a disease implicated for 50% of epithelial defects.⁶ During the 3-month follow-up, no recurrence was observed.

Case 3

A 36-year-old man was monitored in our department for 6 weeks because a PED had appeared in his left eye 4




FIGURE 1. Slit-lamp images of the left eye (case 1) at initiation (A, B), 1 week (C, D), and 3 weeks (complete epithelial healing; E, F) after the combined treatment of an RGTA (Cacicol20) with BCL.




FIGURE 2. Slit-lamp images of the left eye (case 2) before (A, B) and 4 days (complete epithelial healing; C, D) after the combined treatment of an RGTA (Cacicol20) with BCL.

months after he had undergone a penetrating keratoplasty. The graft PED was treated unsuccessfully over the 6-week period with conventional treatment, including lubricants, BCL, short-acting absorbable punctal plugs, antibiotics, and pressure patch. The application of A new therapeutic agent was decided because the PED was unresponsive to conventional therapy during this period.

F3 On the first day of the washout period, the slit-lamp examination showed a peripheral epithelial defect [2.2 mm (height) × 1.0 mm (width)] (Fig. 3A). There was no conjunctival or palpebral abnormality. Intraocular pressure measured values were within normal limits. The epithelial defect did not improve during the washout period. Five days after the combined treatment commenced, the dimensions of the epithelial defect decreased (Fig. 3B). Nine days after the combined treatment started, the slit-lamp examination showed complete corneal epithelial healing (Fig. 3C). During the 3-month follow-up, no recurrence was observed.

DISCUSSION

Several treatments have been proposed for the treatment of PEDs such as artificial tears, eye patching, tarsorrhaphy, fibronectin, autologous serum eye drops, nerve growth factor, amniotic membrane, and topical application of autologous limbal stem cells.^{1–5} BCL has been successfully used in the reepithelialization process and enhancement of corneal healing.^{6,7} However, in some cases, these treatments have poor therapeutic outcomes. Additionally, a combination of BCL with serum eye drops or epidermal growth factor has been reported to be an effective approach for the treatment of

PEDs.^{8–10} Nevertheless, treatment failure for PEDs may occur even after these combined treatments are given.

AU7 RGTA's compose a family of biodegradable glucose-based polymers engineered to replace heparan sulfates.¹¹ RGTA's mimic the action of destroyed heparan sulfate molecules, break the negative repair–destruction cycle occurring in chronic lesions and inhibit proteolytic enzymes in vitro.^{11,14} Experimental studies have already reported the efficacy of RGTA's.^{15,16} In a corneal alkali-burn model, RGTA treatment seemed to be effective in reducing the clinical signs of inflammation, enhancing reepithelialization, and improving histological patterns such as edema, fibrosis, neovascularization, and inflammation.¹⁵ In a recent experimental study, RGTA's facilitated the healing of alkali-injured rabbit corneas via the reduction of proteolytic, oxidative, and nitrosative damage.¹⁶

AU8 An RGTA (Cacicol20) matrix therapy agent has already been used as a monotherapy for the treatment of ocular surface disorders such as neurotrophic ulcers and keratitis and has provided encouraging results.^{12,13} Aifa et al¹² reported corneal healing in 8 of 11 patients treated with an RGTA (Cacicol20) as a monotherapy at a dosage of a single drop every 2 days, with 1 case of recurrence. In another study, Chebbi et al¹³ treated 11 eyes (6 with keratitis and 5 with corneal ulcers) with 1 drop of an RGTA (OTR4120) weekly, and reported a moderate efficacy on keratitis and a favorable effect on the healing of corneal ulcers. This topical RGTA replaces the destroyed heparan sulfates and binds to matrix proteins to protect them from proteolysis; the extracellular matrix microenvironment protection improves the production of signals and growth factors needed for tissue healing.¹¹






FIGURE 3. Slit-lamp images of the left eye (case 3), at initiation (A), 5 days (B), and 9 days (complete epithelial healing; C) after the combined treatment of an RGTA (Cacicol20) with BCL.

In our article, we report a new treatment approach of combined RGTA (Cacicol20) with a BCL for treatment of PEDs. In particular, we describe our experience of this combined treatment in 3 patients who presented with a PED for 4–8 weeks. All patients after topical daily instillation of an RGTA (Cacicol20) combined with a silicon hydrogel BCL improved their clinical condition (complete corneal epithelial healing at 4–21 days). No deposits on the BCL surfaces were observed in any of the patients during the treatment period.

We decided to combine this novel agent (RGTA; Cacicol20) with BCL because the BCL protects the cornea from additional mechanical injury, whereas the RGTA (Cacicol20) enhances epithelial healing. RGTA (Cacicol20) improves the reepithelialization process and enhances extracellular matrix remodeling, optimizing wound healing.¹² The combined therapeutic approach of an RGTA (Cacicol20) with BCL was successfully used in all 3 patients to achieve tissue reconstruction and homeostasis restoration. Despite the limitation of the small number of patients included, all patients, who were unresponsive to the usual approaches, were treated successfully after they had received the combined therapy.

In conclusion, the combination of RGTA (Cacicol20) with a BCL seems to be an effective alternative therapeutic approach for the treatment of PEDs, which takes the pharmaceutical boundaries outside the already known and established treatment regimens, because now the target is the extracellular matrix of the cornea. However, further studies with a larger number of patients are needed to evaluate treatment potential.

REFERENCES

- Jeng BH, Dupps WJ Jr. Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects. *Cornea*. 2009;28:1104–1108.
- Lee SH, Tseng SC. Amniotic membrane transplantation for persistent epithelial defects with ulceration. *Am J Ophthalmol*. 1997;123:303–312.
- Agorogiannis GI, Alexaki VI, Castana O, et al. Topical application of autologous adipose-derived mesenchymal stem cells (MSCs) for persistent sterile corneal epithelial defect. *Graefes Arch Clin Exp Ophthalmol*. 2012;250:455–457.
- Phan TM, Foster CS, Boruchoff SA, et al. Topical fibronectin in the treatment of persistent corneal epithelial defects and trophic ulcers. *Am J Ophthalmol*. 1987;104:494–501.
- Bonini S, Lambiase A, Rama P, et al. Topical treatment with nerve growth factor for neurotrophic keratitis. *Ophthalmology*. 2000;107:1347–1351.
- Blackmore SJ. The use of contact lenses in the treatment of persistent epithelial defects. *Cont Lens Anterior Eye*. 2010;33:239–244.
- Grentzelos MA, Plainis S, Astyrakakis NI, et al. Efficacy of 2 types of silicone hydrogel bandage contact lenses after photorefractive keratectomy. *J Cataract Refract Surg*. 2009;35:2103–2108.
- Choi JA, Chung SH. Combined application of autologous serum eye drops and silicone hydrogel lenses for the treatment of persistent epithelial defects. *Eye Contact Lens*. 2011;37:370–373.
- Holland S, Morck D, Schultz C. Treatment of corneal defects with delayed re-epithelialization with a medical device/drug delivery system for epidermal growth factor. *Clin Experiment Ophthalmol*. 2012;40:662–668.
- Schrader S, Wedel T, Moll R, et al. Combination of serum eye drops with hydrogel bandage contact lenses in the treatment of persistent epithelial defects. *Graefes Arch Clin Exp Ophthalmol*. 2006;244:1345–1349.
- Barritault D, Caruelle JP. Regenerating agents (RGTA): a new therapeutic approach [in French]. *Ann Pharm Fr*. 2006;64:135–144.
- Aifa A, Gueudry J, Portmann A, et al. Topical treatment with a new matrix therapy agent (RGTA) for the treatment of corneal neurotrophic ulcers. *Invest Ophthalmol Vis Sci*. 2012;53:8181–8185.

13. Chebbi CK, Kichenin K, Amar N, et al. Pilot study of a new matrix therapy agent (RGTA OTRA4120) in treatment-resistant corneal ulcers and corneal dystrophy [in French]. *J Fr Ophthalmol*. 2008;31:465–471.
14. Rouet V, Meddahi-Pellé A, Miao HQ, et al. Heparin-like synthetic polymers, named RGTAs, mimic biological effects of heparin in vitro. *J Biomed Mater Res A*. 2006;78:792–797.
15. Brignole-Baudouin F, Warnet JM, Barritault D, et al. RGTA-based matrix therapy in severe experimental corneal lesions: safety and efficacy studies. *J Fr Ophthalmol*. 2013;36:740–747.
16. Cejkova J, Olmiere C, Cejka C, et al. The healing of alkali-injured cornea is stimulated by a novel matrix regenerating agent (RGTA, CACI-COL20): a biopolymer mimicking heparan sulfates reducing proteolytic, oxidative and nitrosative damage. *Histol Histopathol*. 2014;29:457–478.